Breast cancer
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Who can joinWomen
Age18+ years
Kind of studyPhase 2: does it work?
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
7 hospitals in India taking patients for this trial.
HCG City Cancer CenterVijayawada, Andhra PradeshDirections ↗
Narayana Hrudayala Majumdar Shaw HospitalBangalore, KarnatakaDirections ↗
Tata Memorial CentreMumbai, MaharashtraDirections ↗
Mumbai Oncocare CentreMumbai, MaharashtraDirections ↗
Sahyadri Super Speciality HospitalPune, MaharashtraDirections ↗
Nobel HospitalPune, MaharashtraDirections ↗
Health Point HospitalKolkata, West BengalDirections ↗
Registry summary (technical)
This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.
Sponsor: Rhizen Pharmaceuticals SA
NCT06189209 on ClinicalTrials.gov
Last updated on the registry 2 Dec 2025 · read by us 20 Oct 2026